| __timestamp | Bio-Techne Corporation | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 22732000 |
| Thursday, January 1, 2015 | 144969000 | 29245000 |
| Friday, January 1, 2016 | 162364000 | 33206000 |
| Sunday, January 1, 2017 | 188462000 | 31152000 |
| Monday, January 1, 2018 | 210850000 | 10136000 |
| Tuesday, January 1, 2019 | 240515000 | 45546000 |
| Wednesday, January 1, 2020 | 255497000 | 43367000 |
| Friday, January 1, 2021 | 298182000 | 81413000 |
| Saturday, January 1, 2022 | 349103000 | 139304000 |
| Sunday, January 1, 2023 | 366887000 | 192361000 |
| Monday, January 1, 2024 | 389335000 |
Unleashing the power of data
In the ever-evolving biotech industry, cost efficiency is a critical metric for success. From 2014 to 2023, Bio-Techne Corporation and Halozyme Therapeutics, Inc. have showcased contrasting trajectories in managing their cost of revenue. Bio-Techne has consistently increased its cost efficiency, with a notable 266% rise over the decade, peaking at $389 million in 2023. In contrast, Halozyme's cost of revenue surged by an impressive 747%, reaching $192 million in 2023. This stark difference highlights Bio-Techne's steady growth strategy compared to Halozyme's rapid expansion. However, data for 2024 remains incomplete, leaving room for speculation on future trends. As these companies continue to innovate, their financial strategies will play a pivotal role in shaping their competitive edge in the biotech landscape.
Cost Insights: Breaking Down Novartis AG and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Bio-Techne Corporation
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Halozyme Therapeutics, Inc.
Bio-Techne Corporation vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Bio-Techne Corporation vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bio-Techne Corporation vs Perrigo Company plc
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Evotec SE's Expenses